The Synergetic Effect of 188Re-Anti-cea-mcab and Interleukin 12 Gene in Colon Cancer Therapy
Xing Chen,Zengli Liu,WU Wei-yi,Qian Jiang,Yu Qiuxin,Ling Zhou,Fan Wo
2005-01-01
Abstract:Objective To observe the synergetic anti-tumor effect of ~(188)Re-anti-carcinoembryonic an- tigen(CEA)-monoelonal antibody(C50)and interleukin(IL)12 gene on the mice bearing colon cancer. Methods After established the tumor model,chemotherapy(CT),~(188)Re-C50 radioimmunotherapy(RIT), IL12 gene therapy(GT)and GT combined with RIT(GT+RIT)were given in each group.Their anti-tumor effect was compared by measuring tumor volume and weight.The proportion of S,G_1 phase tumor cells was examined by flow cytometry(FCM).Meanwhile,the serumal levels of IL12 in RIT,GT and RIT+GT groups were measured by enzyme-linked immunosorbent assay(ELISA).Results Three weeks after treat- ment tumor volume and weight in RIT and GT+RIT groups were significantly lower than that in control and CT goups(P0.01);the obvious difference existed between RIT and RIT+GT groups.Apoptotic sub-G_1 peak could be observed in FCM histogram 6 h later after RIT,GT and GT+R1T.The S phase ratios of tumor cells in RIT,GT,GT+RIT and control groups were 10.41%,27.53%,6.25% and 33.14%,respectively. The G_0~G_1 phase ratios of tumor cells in RIT,GT,GT+RIT and control groups were 68.60%,53.54%, 72.21% and 35.12%,respectively.The serum level of IL12 was highest in R1T+GT group,and the obvious differences existed also between RIT,GT and RIT+GT groups(P0.01).Conclusions ~(188)Re-C50 RIT combined with IL12 GT can inhibit the growth of colon cancer more effectively in tumor-bearing mice than oth- er therapies,thereby,it shows synergetic anti-tumor effect on colon cancer.RIT+GT can increase the G_0 G_1 phase ratio of tumor cells but decrease the S phase ratio of tumor cells.Apparently,~(188)Re-C50 can up- regulate the expression of IL12 gene.